These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10600193)

  • 21. An international collaborative study of the effect of active pertussis toxin on the modified Kendrick test for acellular pertussis vaccines.
    Xing D; Gaines Das R; Douglas-Bardsley A; Asokanathan C; Corbel M
    Biologicals; 2014 Mar; 42(2):101-8. PubMed ID: 24388289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Standardization of acellular pertussis vaccines.
    Kreeftenberg JG
    Biologicals; 1999 Jun; 27(2):115-7. PubMed ID: 10600198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cloning and expression of subunit genes of pertussis toxin and its immunological evaluation].
    Han F; Liu D; Xiao Z
    Zhonghua Yi Xue Za Zhi; 1998 Apr; 78(4):257-60. PubMed ID: 10923478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acellular pertussis vaccines: new preparation. Better tolerated but less active?
    Prescrire Int; 2000 Feb; 9(45):204-7. PubMed ID: 11503797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Native and genetically inactivated pertussis toxins induce human dendritic cell maturation and synergize with lipopolysaccharide in promoting T helper type 1 responses.
    Ausiello CM; Fedele G; Urbani F; Lande R; Di Carlo B; Cassone A
    J Infect Dis; 2002 Aug; 186(3):351-60. PubMed ID: 12134231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Composition of acellular pertussis and combination vaccines: a general review.
    Jadhav SS; Gairola S
    Biologicals; 1999 Jun; 27(2):105-10. PubMed ID: 10600195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines.
    Geier DA; Geier MR
    Brain Dev; 2004 Aug; 26(5):296-300. PubMed ID: 15165669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of the infant immune responses by the first pertussis vaccine administrations.
    Mascart F; Hainaut M; Peltier A; Verscheure V; Levy J; Locht C
    Vaccine; 2007 Jan; 25(2):391-8. PubMed ID: 17116347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of the new acellular recombinant pertussis vaccine.
    Rappuoli R; Pizza M; Podda A; De Magistris MT; Ceccarini C; Nencioni L
    Arch Inst Pasteur Tunis; 1994; 71(3-4):557-63. PubMed ID: 8801858
    [No Abstract]   [Full Text] [Related]  

  • 30. Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection.
    Fischer JE; Johnson JE; Johnson TR; Graham BS
    J Infect Dis; 2000 Oct; 182(4):1029-38. PubMed ID: 10979896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The immunological basis of the administration of DTP-polio vaccine].
    Cohen H
    Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection.
    Alonso S; Pethe K; Mielcarek N; Raze D; Locht C
    Infect Immun; 2001 Oct; 69(10):6038-43. PubMed ID: 11553541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
    Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
    Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP.
    Robbins JB; Schneerson R; Keith JM; Shiloach J; Miller M; Trollors B
    Vaccine; 2007 Apr; 25(15):2811-6. PubMed ID: 17291636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model.
    Marr N; Oliver DC; Laurent V; Poolman J; Denoël P; Fernandez RC
    Vaccine; 2008 Aug; 26(34):4306-11. PubMed ID: 18582518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines.
    Markey K; Asokanathan C; Feavers I
    Toxins (Basel); 2019 Jul; 11(7):. PubMed ID: 31319496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of adenyl cyclase toxin constructs from Bordetella pertussis as candidate vaccine components in an in vitro model of complement-dependent intraphagocytic killing.
    Prior S; Fleck RA; Gillett ML; Rigsby PR; Corbel MJ; Stacey GN; Xing DK
    Vaccine; 2006 May; 24(22):4794-803. PubMed ID: 16675078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes of the Swedish Bordetella pertussis population in incidence peaks during an acellular pertussis vaccine period between 1997 and 2004.
    Advani A; Donnelly D; Gustafsson L; Hallander HO
    APMIS; 2007 Apr; 115(4):299-310. PubMed ID: 17504296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children.
    Lacombe K; Yam A; Simondon K; Pinchinat S; Simondon F
    Vaccine; 2004 Dec; 23(5):623-8. PubMed ID: 15542182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A recombinant DNA approach to the pertussis vaccine.
    Rappuoli R; Nicosia A; Bartoloni A; Aricò B; Perugini M
    Ann Sclavo Collana Monogr; 1986; 3(1-2):183-9. PubMed ID: 2892506
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.